BSE filing, NSE: NATIONSTD. Summary written from the filing by ALFA Finder's alert engine.
National Standard (India) Ltd: key numbers
- Share price
- ₹105.55
- Market cap
- ₹211.1 Cr
- Revenue (annual)
- ₹20.42 Cr
- Net profit (annual)
- ₹9.66 Cr
- P/E (TTM)
- 20.5×Sector 33.7×
- Promoter holding
- 73.94%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from National Standard (India) Ltd
All →National Standard (India) Q2 FY27 Results: Net Profit ₹3.3 Cr, Down 23.3% YoY
National Standard (India) Ltd reported net profit of ₹3.3 Cr (-23.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹3.3 Cr · -23.3% YoY
National Standard (India) Other Announcement
National Standard (India) Ltd filed its quarterly shareholding pattern for the period ending September 30, 2026. This is a routine regulatory disclosure under Regulation 31(1)(b).
National Standard (India) Acquisition
National Standard (India) Ltd shareholders approved the scheme of merger by absorption with Lodha Developers Limited at the NCLT-convened meeting.
National Standard (India) Merger & Restructuring
National Standard (India) Limited issued a notice for an NCLT-convened shareholder meeting on October 9, 2026, to approve the scheme of merger.
National Standard (India) Acquisition
National Standard (India) Ltd issued notice for an NCLT-convened shareholder meeting on October 09, 2026, to consider its proposed merger with Lodha Developers Ltd.
National Standard (India) Annual General Meeting
National Standard (India) Ltd successfully concluded its 63rd Annual General Meeting on August 28, 2026. All proposed business items were passed by the requisite majority.
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.